Drug Delivery Business

How CGM tech has advanced in the 21st century

By

Eversense CGM Senseonics
The Eversense CGM [Image courtesy of Senseonics]

CGM monitoring for weeks

2018: FDA approves the Eversense CGM system

The Eversense CGM from Senseonics provides glucose data every five minutes for up to 90 days via an implantable sensor. A transmitter and mobile app round out the system. The company’s Eversense XL system, which has a 180-day lifespan, is awaiting FDA approval.

2020: FreeStyle Libre 2 wins FDA clearance

Abbott’s FreeStyle Libre 2, which was introduced in the U.S. in 2020, is an integrated continuous glucose monitor rather than a flash glucose monitor. It notifies users when glucose levels are high or low without requiring them to scan the device. The device is the first patient-facing CGM to have a 14-day lifespan.

The top 10 medical disruptors of 2021>>

IN CASE YOU MISSED IT

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.